NASDAQ:BMEA Biomea Fusion Q2 2025 Earnings Results & Report $0.60 +0.05 (+9.69%) As of 10:58 AM Eastern This is a fair market value price provided by Massive. Learn more. Biomea Fusion beat analyst earnings expectations in its Q2 2025 results, released August 5, 2025. The company reported EPS of -$0.51 versus the -$0.59 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2025Report DateAugust 5, 2025TimeBefore Market OpensConference Call7:00 AM ET Biomea Fusion EPS ResultsActual EPS-$0.51Consensus EPS -$0.59Beat/MissBeat by +$0.08One Year Ago EPSN/AEPS Beat Rate7 of last 8 quartersBiomea Fusion Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Biomea Fusion Q2 2025 Earnings FAQ Did Biomea Fusion beat earnings estimates for Q2 2025? Biomea Fusion (NASDAQ:BMEA) reported earnings of -$0.51 per share for Q2 2025, beating the consensus estimate of -$0.59. The report was announced on Tuesday, August 5, 2025. Biomea Fusion Earnings HeadlinesBiomea Fusion Reports Third Quarter 2026 Financial Results and Corporate HighlightsNovember 10 at 4:05 PM | globenewswire.comBiomea Fusion Announces Poster Presentation of Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist, at ObesityWeek® 2026November 10 at 7:00 AM | globenewswire.com55+? Elon’s Gift…James Altucher points to Elon Musk's latest FCC filing as a potential turning point for retirees relying on Social Security. While seniors are getting a raise of about $75 a month, SpaceX turned 4,400 people into millionaires overnight, and Tesla created so many that the press coined the term 'Teslanaires.' By Altucher's estimates, Musk has created around 100,000 millionaires so far. He believes this filing could produce 1.8 million more.November 11 at 1:00 AM | Paradigm Press (Ad)Biomea Fusion (BMEA) Projected to Post Quarterly Earnings on TuesdayNovember 2, 2026 | americanbankingnews.comWhat's going on with Biomea Fusion (BMEA) stock after hours?October 14, 2026 | msn.comBiomea Reports Phase 1 Weight-Loss Data For Oral GLP-1 Candidate BMF-650; Shares FallOctober 13, 2026 | rttnews.comSee More Biomea Fusion Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Biomea Fusion? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biomea Fusion and other key companies, straight to your email. Email Address About Biomea FusionBiomea Fusion (NASDAQ:BMEA) is a clinical-stage biopharmaceutical company focused on developing small-molecule medicines for cancer and metabolic diseases. The company uses its proprietary FUSION System to discover and develop covalent medicines designed to engage disease-relevant protein targets. Biomea’s lead investigational product is BMF-219, an oral, selective covalent inhibitor of menin. The company has evaluated BMF-219 in clinical studies for certain hematologic malignancies and solid tumors, including acute leukemias and multiple myeloma, and has also investigated its potential in metabolic diseases such as type 2 diabetes. BMF-500 is another investigational program intended to target menin-related biology. Founded in 2017 and headquartered in Redwood City, California, Biomea Fusion conducts research and clinical development activities aimed at addressing diseases with significant unmet medical needs. The company is led by Thomas Butler, who serves as co-founder, chairman and chief executive officer. Its programs are investigational and have not been approved for commercial use by regulatory authorities.View Biomea Fusion ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Amazon's Rally Is Outpacing Big Tech, But Can AWS Justify the AI Spending?Aehr Test Systems Notches Another Post-Earnings Win as Sales Triple on AI DemandThe Trade Desk Beats on Revenue, But the Fine Print MattersWhy Kinder Morgan's Chairman Just Bought $15 Million in StockA $4 Billion Jolt: NRG Energy Powers Data Center Ambitions3 Stocks Wall Street Likes More Than the Market DoesD-Wave Quantum Has Long-Term Potential, But Is Now the Time to Buy? Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
